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  BACKGROUND:  The  prevalence  of  Congestive  Heart  Failure  (CHF)  is  increasing  in  recent 
years.  Factors  associated  with  mortality  in  CHF  patients  are  important  to  be  determined  in 
order to select therapeutic modality by physicians. The purpose of the current study was to 
declare  predictors  of  6-months  survival  in  patients  hospitalized  for  decompensated  CHF  in 
Isfahan. 
  METHODS: A cohort of 301 hospitalized patients with decompensated CHF were recruited in 
this  study.  The  diagnosis  of  CHF  was  based  on  previous  hospitalizations  and  Framingham 
criteria for heart failure (HF). Information regarding past history, accompanying diseases such 
as cerebrovascular accidents (CVA), chronic obstructive pulmonary diseases (COPD), clinical 
data, medications and echocardiography were obtained by a cardiologist. Patients were followed 
for their survival for 6 months by telephone calls. Kaplan-Meier method was used for uni variate 
survival analysis and Cox proportional hazard model was used for multivariate analysis. 
  RESULTS: Mean age of patients was 71.9 ± 12.2 years and 59.8% was male. During 6-months 
follow-up  138  (45.8%)  patients  died.  Mean  survival  was  119.2  ±  4.4  days  (Mean  ±  SEM). 
Significant prognostic factors for 6 months survival were high education level (HR = 0.74, CI 
95% 0.59—0.93), COPD (HR = 1.91, CI 95% 1.2—3.04), CVA (HR = 1.69, CI 95% 1.03—2.78), 
Angiotensin  Converting  enzyme  (ACE)  inhibitors  use  (HR  =  0.44,  CI  95%  0.3—0.66)  and 
Diuretics (HR = 0.63, CI 95% 0.41-0.96). 
  CONCLUSION: Six-month survival of hospitalized decompensated CHF patients in Iran is not 
favorable.  Many  factors  particularly  accompanying  diseases  and  medications  affected  the 
patient’s 6-months survival. 
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Introduction 
One  of  the  important  cardiac  diseases  with  poor 
prognosis is congestive heart failure (CHF). In recent 
years it has become one of the most important public 
health problems in cardiovascular medicine.1 Despite 
effective improvement in therapeutics during the past 
two  decades,  CHF  remains  a  major  cause  of 
cardiovascular morbidity and mortality. Aging of the 
population and survival improvement of patients with 
cardiovascular disease (CVD) by modern therapeutic 
innovations  has  led  to  the  increasing  prevalence  of 
CHF.2-4  
  Since  1980,  many  studies  have  been  reported  a 
progressive  improvement  in  the  survival  of  CHF 
patients.5  However,  the  average  survival  remained 
poor after hospitalization for the first episode of or 
decompensated CHF.5,6 Mortality rate have increased 
after CHF hospitalization, even after adjustment for 
baseline  predictors  of  death  .7The  increased risk  of 
death was highest within one month of discharge and 
declined progressively over time.6 
  Despite the available data on other CVD, There 
are few data regarding CHF mortality and morbidity 
in  Iran.  Determining  predicting  factors  that PROGNOSTIC FACTORS FOR SURVIVAL AT 6-MONTH FOLLOW-UP OF HOSPITALIZED PATIENTS 
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one related to mortality and morbidity of hospitalized 
decompensated  CHF  patients  may  help  identify 
which  patients  need  intensive  monitoring  during 
hospitalization and after discharge. 
  So,  the  aim  of  this  study  was  to  determine  the 
predictors  of  6-months  survival  in  patients 
hospitalized for decompensated CHF in Isfahan. 
 
Materials and Methods 
Data collection: This cohort included 301 patients, 
hospitalized for decompensated CHF in two referral 
hospital  for  cardiac  patients.  As  there  two  referral 
centers  sample  was  representative  of  the  patient’s 
community.  The  diagnosis  was  done  based  on 
Framingham  criteria  of  CHF  by  a  cardiologist6,8. 
Acute decompensation of CHF was defined by the 
presence of an acute increase of shortness of breath, 
pulmonary rales, vascular enlargement and/or frank 
edema  detected  by  chest  X-ray  at  the  time  of 
admission9,10.  At  first  a  questionnaire  was  filled 
including  demographics  (sex,  age,  educational  level, 
marital status and smoking (cigarette and /or opium 
history), medications such as (angiotensin converting 
enzyme (ACE) inhibitors, diuretics, beta blockers and 
other drugs). The history of diabetes mellitus (DM), 
myocardial  infarction  (MI),  chronic  obstructive 
pulmonary  disease  (COPD),  renal  disease  and 
hypertension (HTN) were recorded. 
  Each patient underwent an echocardiography by a 
cardiologist.  A  thorough  two-dimensional  and 
Doppler  echocardiographic  study  was  performed 
according  to  a  standard  imaging  protocol.  Ejection 
fraction (EF) was determined. All measurement was 
done  by  VIVID  3  echocardiography  machine, 
manufactured in 2006, General Electric Company. EF 
more  or  less  than  50%  was  considered  normal  or 
low11. Blood pressure was taken by standard protocol 
at the time of echocardiography12.  
  After discharge, patients were followed up for 6 
months  by  telephone  calls.  Survival  status  was 
assessed by telephone contact with family members 
and verified by studying hospital records. At the end 
of  the  follow-up  period,  the  collected  data  were 
subjected to statistical analysis. 
 
Statistical  analysis:  At  the  first  step,  data  were 
described  in  tables  and  shown  with  central  and 
distributional statistical indices. Then, survival analysis 
was done. Survival curves were plotted and stratified 
by EF groups using the Kaplan Meier method. The 
log-rank test was used to test for differences between 
the survival curves. Cox proportional hazards model 
was used for multivariate analysis. Statistical analyses 
were performed via SPSS for Windows, version 15; 
 
Table 1. Baseline characteristics of CHF patients 
Variable  Frequency  % 
Sex  Male  180  59.8 
Female  121  40.2 
Age (years)  <65  80  26.6 
≥65  221  73.4 
Marital Status  Single   35  11.6 
Married  266  88.4 
Education 
Illiterate  115  38.2 
Primary school  94  31.2 
Intermediate school  3  1 
Diploma  81  26.9 
Above diploma  8  2.7 
Current Smoker  No  262  87 
Yes  39  13 
Opium Addict  No  290  96.3 
Yes  11  3.7 
Diabetes Mellitus  No  192  63.8 
Yes  109  36.2 
Hypertension  No  162  53.8 
Yes  139  46.2 
Myocardial Infraction  No  241  80.1 
Yes  60  19.9 
Cerebrovascular Accident  No  273  90.7 
Yes  27  9.3 
COPD*  No  264  87.7 
Yes  37  12.3 
Renal Diseases  No  273  90.7 
Yes  28  9.3 
 
COPD*: Chronic Obstrutive Pulmonary Disease Cheraghi M, Sadeghi M, Sarrafzadegan N, Pourmoghadas A, Ramezani M A   
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Table 2. Frequency of medication use in patients 
Drug  Number  Frequency 
% 
ACEI* 
No  79  26.2 
Yes  222  73.7 
Diuretics 
No  49  16.3 
Yes  252  83.7 
Beta 
blocker 
No  233  77.4 
Yes  68  22.6 
Other 
medication 
No  44  14.6 
Yes  257  85.4 
 
ACEI*: Angiotensin Converting Enzyme Inhibitors 
 
(SPSS  Inc.,  Chicago,  IL).  Parametric  data  are 
presented as mean±SD or mean±SEM.  
  P  value  <0.05  was  considered  statistically 
significant. 
 
  Ethical issues: The study was approved by the 
Ethics Committee in Isfahan Cardiovascular Research 
Center, WHO- Collaborating Center for Research and 
Training in Cardiovascular Diseases Control. 
 
Results 
We recruited 301 patients aged 19-92 years old,with 
decompensated  CHF  who  were  admitted  to  the 
cardiology departments in two referral hospital. The 
baseline characteristics of studied patients have been 
shown  in  table  1.Mean  age  of studied  patients  was  
71.9±12.2. 
  During hospitalization, normal and low EF were 
seen  in  43  (14.3%)  and  258  (85.7%)  of  patients, 
respectively. Mean level of EF was 29.5%±14.5. Most 
of patients were on medication and ACE inhibitors 
and diuretics were the major drugs which were used 
by patients (Table 2).  
  During  6-months  follow-up  45.8%  (138)  of 
patients  died.  Mean  survival  was  119.2±4.4  days 
(Mean±SEM).  We  compared  the  survival  between 
patients with normal and low EF. Kaplan-Meier analysis 
with log rank test did not show any significant differences 
between two groups (Figure 1). 
  For  determining  the  different  groups  of 
prognostic factors on survival of patients with CHF, 
three  multivariate  models  of  Cox’  regressions  were 
run. The first model was done on socio-demographic 
variables  (Sex,  age,  education,  marital  status,  and 
smoking habits). The second model was based on co-
morbid diseases like HTN, DM, MI, CVA, COPD, 
and  renal  disease.  The  third  hazard  model  was 
selected  on  the  drug  prescription.  The  predictive 
Time of survival - Day

























Figure 1- Survival of hospitalized decompensated CHF patients with normal and low EF 
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Table 3- Independent predictors of 6-months survival of hospitalized decompensated CHF patients 
  Predictors  Hazard Ratio  95% CI  P value 
Model 1 
Sex (female)  1.03  0.72—1.48  N.S* 
Age ≥65 years  1.58  0.81—3.07  N.S 
Education  0.74  0.59—0.93  0.01 
Marital Status (married)  0.69  0.39—1.22  N.S 
Current smoker  1.12  0.64—1.94  N.S 
Opium addict  0.71  0.30—1.68  N.S 
Model 2 
Diabetes Mellitus  1.22  0.85—1.78  N.S 
Hypertension  0.69  0.48—1  N.S 
COPD**  1.91  1.20—3.04  0.007 
Myocardial infarction  1.17  0.78—1.76  N.S 
Cerebrovascular accident  1.69  1.03—2.78  0.037 
Renal Disease  1.13  0.65—1.98  N.S 
Model 3 
ACEI¶  0.44  0.30—0.66  <0.001 
Diuretics  0.63  0.41—0.96  0.03 
Beta Blockers  0.77  0.49—1.21  N.S 
Other Medications  1.59  0.91—2.78  N.S 
 
NS *: Non significant 
COPD **: Chronic Obstrutive Pulmonary Disease 
ACEI¶: Angiotensin Converting Enzyme Inhibitors 
 
 




Our study provides a 6-month follow-up of a cohort 
of  patients  with  CHF  who  were  admitted  in  two 
referral  hospitals  in  Isfahan  city.  In  this  study,  we 
present  prognostic factors regarding  the  survival  of 
these patients. 
  Mortality of CHF during the 6-month follow-up 
was 45.8%. Previous study reported a mortality rate 
of 22% during 6-month follow-up in their study in 
200513.  However,  other  studies  showed  different 
mortality  rate  of  2%  after  one  year  follow-up14. 
Another study from Denmark presented 54% death 
rate15.  On  the  other  hand,  a  study  in  Spain 
demonstrated death rate of CHF to be 66.3%5. The 
follow-up period in both studies was 5 years5,15. The 
death  rate  of  decompensated  hospitalized  CHF 
patients  after  6-months  follow-up  was  very  high  in 
our study. It seems that it depends on factors such as 
medical care and new technology, etiology of CHF, 
EF  level  and  socioeconomic  factors.  Moreover, 
different case selection and definitions, or ethno-racial 
differences  many  lead  to  various  results  between 
studies.  In  our  study  we  recruited  hospitalized 
decompensated CHF patients. 
  One  of  prognostic  factor  on  CHF  is  EF. 
However, nearly, 14% of our patients had a normal 
EF  and  their  outcome  regarding  mortality  and 
morbidity was severe as in patients with reduced EF16. 
Some  studies  have  showed  that  EF  alone  is  not  a 
predictive factor for CHF Prognosis17 whereas other 
echocardiographic findings like diastolic dysfunction 
and left ventricular hypertrophy play important roles 
in prognosis of CHF patients17. In our study, there 
was no significant difference between the survival of 
CHF patients with normal EF and reduced EF that 
may be due to other variables that we did not include 
in the study. 
  Multivariate  analysis  in  the  current  study 
demonstrated that comorbid diseases like COPD and 
CVA were prognostic factors for mortality in CHF 
patients.  In  contrast,  high  educational  level  and 
prescription of ACEIs and diuretics play protective 
role in the survival of CHF patients. 
  Although it has been reported that some factors 
such as comorbid diseases, anemia, some biochemical PROGNOSTIC FACTORS FOR SURVIVAL AT 6-MONTH FOLLOW-UP OF HOSPITALIZED PATIENTS 
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markers, hyperlipidemia, cardiac function and markers 
of physical performance affect the survival of CHF 
patients,  18, but in our study, we could not study all 
factors.  Another  reason  for  the  difference  between 
our and other reports is the diversity in the prognosis 
of  CHF,  depending  on  the  methods  used  for 
diagnostic  purposes,  the  study  design,  and  the 
underlying  diseases.  Investigations  about  CHF  have 
been done in various distinct populations that include 
outpatients19-21,  inpatients  hospitalized  for  disorders 
other than CHF22, in patients with new onset CHF23 
or patients hospitalized for worsened CHF.10,24-26 
  We had some limitations in our study. We did not 
assess  biochemical  markers  related  to  CHF. 
Furthermore, the underlying disease of CHF of our 
patients was not determined. 
 
Conclusion 
According to our results, the 6 months prognosis of our 
hospitalized patients for decompensated CHF was poor. 
As  higher  education  level  had  favorable  prognostic 
impact on the survival, actions to improve the patient’s 
awareness and training regarding these diseases may be 
effective.  We  also  suggest  careful  investigation  and 
better  control  of  comorbid  discovers  to  have  better 
survival of CHF patients. 
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